CovidV1, Main, Exploration, bibRecord, 001027

Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models

Identifieur interne : 001027 ( Main/Exploration ); précédent : 001026; suivant : 001028

Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models

Auteurs : Jason Paragas [États-Unis] ; Lawrence M. Blatt [États-Unis] ; Chris Hartmann [États-Unis] ; John W. Huggins [États-Unis] ; Tim P. Endy [États-Unis]

Source :

Antiviral research [ 0166-3542 ] ; 2005.

RBID : Pascal:05-0266873

Descripteurs français

KwdFr :
- Antiviraux (pharmacologie), Effet cytopathogène viral, Humains, Interféron alpha, Interféron de type I (pharmacocinétique), Interféron de type I (pharmacologie), Modèles biologiques, Protéines recombinantes, Tests de sensibilité microbienne, Virus du SRAS ().
MESH :
- pharmacocinétique : Interféron de type I.
- pharmacologie : Antiviraux, Interféron de type I.
Pascal (Inist)
- Cytokine, Effet cytopathogène viral, Humains, Interféron, Interféron alpha, Modèles biologiques, Protéines recombinantes, Tests de sensibilité microbienne, Virus du SRAS, Virus syndrome respiratoire aigu sévère, In vitro, Modèle, Relation structure activité, Syndrome respiratoire aigu sévère, Antiviral, Traitement.

English descriptors

KwdEn :
- Antiviral, Antiviral Agents (pharmacology), Cytokine, Cytopathogenic Effect, Viral, Humans, In vitro, Interferon, Interferon Type I (pharmacokinetics), Interferon Type I (pharmacology), Interferon-alpha, Microbial Sensitivity Tests, Models, Models, Biological, Recombinant Proteins, SARS Virus (drug effects), Severe acute respiratory syndrome, Severe acute respiratory syndrome virus, Structure activity relation, Treatment.
MESH :
- chemical , pharmacokinetics : Interferon Type I.
- chemical , pharmacology : Antiviral Agents, Interferon Type I.
- drug effects : SARS Virus.
- Cytopathogenic Effect, Viral, Humans, Interferon-alpha, Microbial Sensitivity Tests, Models, Biological, Recombinant Proteins.

Abstract

Preliminary data examining interferon alfacon 1 treatment of SARS-CoV (severe acute respiratory syndrome-corona virus)-infected patients suggests this therapy is well tolerated and of therapeutic benefit. We report herein that interferon alfacon 1, has potent in vitro antiviral activity against SARS-CoV. In a cytopathic effect protection (CPE) assay, interferon alfacon inhibited the generation of CPE in a dose-dependent manner with an IC₅₀ of 0.001 μg/ml, a clinically achievable level. Furthermore, interferon alfacon also demonstrated significant antiviral activity in yield reduction and plaque reduction assays. The in vitro antiviral activity of interferon alfacon 1 against SARS-CoV suggests continued evaluation of interferon alfacon 1 as a therapeutic treatment for patients infected with SARS-CoV.

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models</title>
<author><name sortKey="Paragas, Jason" sort="Paragas, Jason" uniqKey="Paragas J" first="Jason" last="Paragas">Jason Paragas</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), 1425 Porter Street</s1>
<s2>Fort Detrick, MD 21702-5011</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Blatt, Lawrence M" sort="Blatt, Lawrence M" uniqKey="Blatt L" first="Lawrence M." last="Blatt">Lawrence M. Blatt</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>InterMune Inc 3280 Bayshore Boulevard</s1>
<s2>Brisbane, CA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hartmann, Chris" sort="Hartmann, Chris" uniqKey="Hartmann C" first="Chris" last="Hartmann">Chris Hartmann</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), 1425 Porter Street</s1>
<s2>Fort Detrick, MD 21702-5011</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Huggins, John W" sort="Huggins, John W" uniqKey="Huggins J" first="John W." last="Huggins">John W. Huggins</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), 1425 Porter Street</s1>
<s2>Fort Detrick, MD 21702-5011</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Endy, Tim P" sort="Endy, Tim P" uniqKey="Endy T" first="Tim P." last="Endy">Tim P. Endy</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), 1425 Porter Street</s1>
<s2>Fort Detrick, MD 21702-5011</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0266873</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0266873 INIST</idno>
<idno type="RBID">Pascal:05-0266873</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000048</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000011</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000047</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000047</idno>
<idno type="wicri:doubleKey">0166-3542:2005:Paragas J:interferon:alfacon:is</idno>
<idno type="wicri:Area/Main/Merge">001038</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15911026</idno>
<idno type="wicri:Area/PubMed/Corpus">000707</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000707</idno>
<idno type="wicri:Area/PubMed/Curation">000707</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000707</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000701</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000701</idno>
<idno type="wicri:Area/Ncbi/Merge">000053</idno>
<idno type="wicri:Area/Ncbi/Curation">000053</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000053</idno>
<idno type="wicri:doubleKey">0166-3542:2005:Paragas J:interferon:alfacon:is</idno>
<idno type="wicri:Area/Main/Merge">001004</idno>
<idno type="wicri:Area/Main/Curation">001027</idno>
<idno type="wicri:Area/Main/Exploration">001027</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models</title>
<author><name sortKey="Paragas, Jason" sort="Paragas, Jason" uniqKey="Paragas J" first="Jason" last="Paragas">Jason Paragas</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), 1425 Porter Street</s1>
<s2>Fort Detrick, MD 21702-5011</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Blatt, Lawrence M" sort="Blatt, Lawrence M" uniqKey="Blatt L" first="Lawrence M." last="Blatt">Lawrence M. Blatt</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>InterMune Inc 3280 Bayshore Boulevard</s1>
<s2>Brisbane, CA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hartmann, Chris" sort="Hartmann, Chris" uniqKey="Hartmann C" first="Chris" last="Hartmann">Chris Hartmann</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), 1425 Porter Street</s1>
<s2>Fort Detrick, MD 21702-5011</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Huggins, John W" sort="Huggins, John W" uniqKey="Huggins J" first="John W." last="Huggins">John W. Huggins</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), 1425 Porter Street</s1>
<s2>Fort Detrick, MD 21702-5011</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Endy, Tim P" sort="Endy, Tim P" uniqKey="Endy T" first="Tim P." last="Endy">Tim P. Endy</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), 1425 Porter Street</s1>
<s2>Fort Detrick, MD 21702-5011</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Cytokine</term>
<term>Cytopathogenic Effect, Viral</term>
<term>Humans</term>
<term>In vitro</term>
<term>Interferon</term>
<term>Interferon Type I (pharmacokinetics)</term>
<term>Interferon Type I (pharmacology)</term>
<term>Interferon-alpha</term>
<term>Microbial Sensitivity Tests</term>
<term>Models</term>
<term>Models, Biological</term>
<term>Recombinant Proteins</term>
<term>SARS Virus (drug effects)</term>
<term>Severe acute respiratory syndrome</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Structure activity relation</term>
<term>Treatment</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (pharmacologie)</term>
<term>Effet cytopathogène viral</term>
<term>Humains</term>
<term>Interféron alpha</term>
<term>Interféron de type I (pharmacocinétique)</term>
<term>Interféron de type I (pharmacologie)</term>
<term>Modèles biologiques</term>
<term>Protéines recombinantes</term>
<term>Tests de sensibilité microbienne</term>
<term>Virus du SRAS ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Interferon Type I</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Interferon Type I</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Interféron de type I</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Interféron de type I</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cytopathogenic Effect, Viral</term>
<term>Humans</term>
<term>Interferon-alpha</term>
<term>Microbial Sensitivity Tests</term>
<term>Models, Biological</term>
<term>Recombinant Proteins</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cytokine</term>
<term>Effet cytopathogène viral</term>
<term>Humains</term>
<term>Interféron</term>
<term>Interféron alpha</term>
<term>Modèles biologiques</term>
<term>Protéines recombinantes</term>
<term>Tests de sensibilité microbienne</term>
<term>Virus du SRAS</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>In vitro</term>
<term>Modèle</term>
<term>Relation structure activité</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Antiviral</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Preliminary data examining interferon alfacon 1 treatment of SARS-CoV (severe acute respiratory syndrome-corona virus)-infected patients suggests this therapy is well tolerated and of therapeutic benefit. We report herein that interferon alfacon 1, has potent in vitro antiviral activity against SARS-CoV. In a cytopathic effect protection (CPE) assay, interferon alfacon inhibited the generation of CPE in a dose-dependent manner with an IC<sub>50</sub>
 of 0.001 μg/ml, a clinically achievable level. Furthermore, interferon alfacon also demonstrated significant antiviral activity in yield reduction and plaque reduction assays. The in vitro antiviral activity of interferon alfacon 1 against SARS-CoV suggests continued evaluation of interferon alfacon 1 as a therapeutic treatment for patients infected with SARS-CoV.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Maryland</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Paragas, Jason" sort="Paragas, Jason" uniqKey="Paragas J" first="Jason" last="Paragas">Jason Paragas</name>
</region>
<name sortKey="Blatt, Lawrence M" sort="Blatt, Lawrence M" uniqKey="Blatt L" first="Lawrence M." last="Blatt">Lawrence M. Blatt</name>
<name sortKey="Endy, Tim P" sort="Endy, Tim P" uniqKey="Endy T" first="Tim P." last="Endy">Tim P. Endy</name>
<name sortKey="Hartmann, Chris" sort="Hartmann, Chris" uniqKey="Hartmann C" first="Chris" last="Hartmann">Chris Hartmann</name>
<name sortKey="Huggins, John W" sort="Huggins, John W" uniqKey="Huggins J" first="John W." last="Huggins">John W. Huggins</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001027 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001027 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    CovidV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:05-0266873
   |texte=   Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models
}}

This area was generated with Dilib version V0.6.33.
Data generation: Fri Mar 27 18:14:15 2020. Site generation: Sun Jan 31 15:15:08 2021

Serveur d'exploration Covid

Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models

Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration Covid
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.